Kerecis was established in 2009 as a research project based in Isafjordur, Iceland.
The company bases its technology on fish skin.
The primary product line (“Kerecis Omega3”) uses intact fish skin for human tissue transplants.
The Kerecis Omega3 fish skin is regulatory approved as medical device in multiple jurisdictions (including U.S. and Europe) for indications such as burn and diabetic wounds.
Regulatory submissions are pending for multiple other indications.
The company’s second product line (“mOmega3”) uses proprietary fatty acids in skin care formulations that are regulatory approved in Europe as medical devices.